Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak - United States, May 22-October 21, 2022

• Published in: MMWR. Morbidity and mortality weekly report 2022-12, Vol.71 (49), p.1555-1559
• Main Authors: Duffy, Jonathan, Marquez, Paige, Moro, Pedro, Weintraub, Eric, Yu, Yon, Boersma, Peter, Donahue, James G, Glanz, Jason M, Goddard, Kristin, Hambidge, Simon J, Lewin, Bruno, Lewis, Ned, Rouse, Douglas, Shimabukuro, Tom
• Format: Article
• Language: English
• Subjects: Adult; Adverse events; Anaphylaxis; Drug dosages; Humans; Immunization; Males; Medical records; Mpox; Mpox (monkeypox) - prevention & control; Myocarditis; Outbreaks; Product Surveillance, Postmarketing; Public health; Regulatory agencies; Safety; Safety and security measures; Smallpox; Smallpox vaccine; Smallpox Vaccine - administration & dosage; Smallpox Vaccine - adverse effects; Surveillance; Vaccines
• ISSN: 0149-2195; 1545-861X
• DOI: 10.15585/mmwr.mm7149a4

JYNNEOS (Modified Vaccinia Ankara vaccine, Bavarian Nordic) is recommended in the United States for persons exposed to or at high risk for exposure to Monkeypox virus during the 2022 monkeypox (mpox) outbreak (1). JYNNEOS is a live, nonreplicating viral vaccine licensed for the prevention of smallpox and mpox in adults aged ≥18 years, administered as a 0.5-mL 2-dose series given 28 days apart by subcutaneous injection (2). On August 9, 2022, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for administration of 0.1 mL doses by intradermal injection for adults aged ≥18 years as a strategy to increase vaccine supply, and administration of 0.5 mL doses subcutaneously for persons aged